Program Resources
Other Resources and Tools
-
Diabetes Canada Pharmacologic Management: 2020 Update
-
Diabetes Canada Pharmacologic Management: 2020 Update – User’s Guide
-
The 2018 Clinical Practice Guidelines - Quick Reference Guide
-
Antihyperglycemic Agents and Renal Function
-
KDIGO Clinical Practice Guideline for the Evaluation and Management of CKD
-
Sick-Day Medication List
-
Pharmacotherapy for Type 2 Diabetes Interactive Tool
-
Reducing Vascular Risk Interactive Tool
-
Self-Monitoring Blood Glucose (SMBG) Interactive Tool
Articles
-
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME)
-
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (CANVAS)
-
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes (DECLARE)
-
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)
-
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER)
-
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy (CREDENCE)
-
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND)
-
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction (DAPA-HF)
-
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (EMPEROR-Reduced)
-
Dapagliflozin in Patients with Chronic Kidney Disease (DAPA-CKD)
Program Materials
-
Program Slides
-
Program Slides for Virtual Sessions
-
Facilitator Guide
-
Patient Worksheet Handout
-
Speaker Training Video
